Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS MUTATION
NRAS MUTATION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1509
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/208
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Binimetinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24588908
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Binimetinib | Sensitivity | true |